Home › Coronary Artery Disease › Florida › Hialeah
Coronary Artery Disease clinical trials in Hialeah, FL
3 studies for Coronary Artery Disease are looking for participants at sites in and around Hialeah (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RecruitingPhase 4
- Inpatient Research Clinic, LLC, Miami Lakes · 4 mi away
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
RecruitingPhase 2
- New Generation of Medical Research, LLC., Hialeah
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Family First Medical Research Center, Hialeah Gardens · 3 mi away
- Floridian Clinical Research, Miami Lakes · 4 mi away
About Coronary Artery Disease
Coronary artery disease (CAD) is the most common type of heart disease. It can lead to angina and heart attack. Read about symptoms and tests.
More about Coronary Artery Disease on MedlinePlus
Coronary Artery Disease trials in other cities
- New York City, NY21 studies
- Boston, MA16 studies
- Dallas, TX15 studies
- Atlanta, GA15 studies
- Jacksonville, FL14 studies
- Minneapolis, MN13 studies
- Cleveland, OH13 studies
- Nashville, TN11 studies
- Columbus, OH10 studies
- Durham, NC9 studies
- Memphis, TN8 studies
- Houston, TX8 studies
Other studies in Hialeah
- Obesity13 studies
- Schizophrenia13 studies
- Heart Failure12 studies
- Type 2 Diabetes10 studies
- Overweight10 studies
- Steatotic Liver Disease9 studies
- COPD8 studies
- Major Depressive Disorder8 studies
- Atherosclerosis8 studies
- Alzheimer's Disease6 studies
- Post-COVID Conditions (Long COVID)6 studies
- Cancer (all types)6 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.